Free Newsletter
'Erratic' behavior triggers Chantix probe
When is quitting smoking a bad thing? When you quit with the help of Pfizer's Chantix, and then settle into a depressive funk so bad, you think about killing yourself. That's just what's happening to some patients, according to the FDA, which asked doctors yesterday to start monitoring those who are taking the drug. The agency has received reports from patients and docs, who say Chantix is triggering depression, severe mood swings, abnormal dream states and suicidal thoughts.
Strange, yes. But even stranger is the event that may have triggered the FDA's investigation. In September, a professional musician taking Chantix--possibly in one of those abnormal dream states--hammered on the door of his neighbor's house, screaming bloody murder. The neighbor shot him. The incident made the morning news shows at the time. Could this be the "case report citing erratic behavior" mentioned by the agency in its press release?
Until now, Chantix has largely been a success story. Its sales have climbed steadily since its launch last year, when it hit the ground running so hard that a Pfizer exec called Chantix its fastest launch ever.
- see the release from the FDA
- read this report on the musician's death and Chantix's early performance
- take a look at this Fortune article
- read a firsthand account of Chantix-enhanced dreaming
Related Articles:
Chantix outperforms Zyban in major study. Report
Addex smoking cessation drug misses endpoint. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





